Can Fite BioPharma Ltd (CANF)

[midastouch017]

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

https://finance.yahoo.com/news/fite-presenting-namodenoson-pancreatic-cancer-110000482.html

PETACH TIKVA, Israel, May 15, 2023--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, today announced its VP of Business Development, Dr. Sari Fishman, will participate in BioEquity Europe which takes place on May 14th – 16th, 2023 in Dublin, Ireland.

Dr. Fishman will conduct one-on-one meetings with potential strategic partners for Can-Fite’s advanced stage pipeline including pharma companies focused on oncology, dermatology, and liver diseases. To date, Can-Fite has monetized its portfolio through out-licensing and distribution deals in select territories.

"We believe Namodenoson’s new indication for the treatment of pancreatic cancer is generating interest from companies that are looking to augment their portfolio with novel solutions for this devastating disease. We look forward to productive meetings at BioEquity," stated Dr. Sari Fishman.

Can-Fite recently announced plans to initiate an open-label Phase 2 exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy. Pre-clinical studies conducted on advanced pancreatic carcinoma patient cells showed Namodenoson had a significant anti-cancer effect.

Acumen Research estimates the global pancreatic cancer therapeutics market was valued at approximately $3.6 billion in 2021 and is projected to grow to approximately $6.6 billion by 2030.